Two therapeutic challenges: facial vitiligo successfully treated with 1% pimecrolimus cream and 0.005% calcipotriol cream

Bilaç, DB; Ermertcan, AT; Sahin, M Turhan; Öztürkcan, Serap

doi:10.1111/j.1468-3083.2008.02668.x

Cited by 7 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Favorable results also occurred in one retrospective study and three case reports . More information regarding major studies can be found in Table …”

Section: Resultsmentioning

confidence: 89%

See 1 more Smart Citation

Efficacy of topical calcineurin inhibitors in vitiligo

Wong¹,

Lin

2013

Int J Dermatology

View full text Add to dashboard Cite

Topical tacrolimus and pimecrolimus are indicated for the treatment of atopic dermatitis, but they have been studied in many off-label uses. We reviewed the English language literature to define their roles in treatment of vitiligo. Double-blind studies show that tacrolimus 0.1% ointment combined with excimer laser is superior to placebo, especially for UV resistant areas, such as bony prominences of the extremities. When used alone, tacrolimus 0.1% ointment is almost as effective as clobetasol propionate 0.05% ointment. Other studies suggest it can also be effective for facial lesions. Double blind studies show that pimecrolimus 1% cream combined with narrow band UVB is superior to placebo, especially for facial lesions. Additional studies would further clarify the role of topical calcineurin inhibitors in vitiligo.

show abstract

“…Favorable results also occurred in one retrospective study and three case reports . More information regarding major studies can be found in Table …”

Section: Resultsmentioning

confidence: 89%

“… Six other open studies involving 144 patients, patients from one retrospective study and three case studies support the use of pimecrolimus 1% cream in the treatment of facial vitiligo. …”

Section: Resultsmentioning

confidence: 89%

Efficacy of topical calcineurin inhibitors in vitiligo

Wong¹,

Lin

2013

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…Several other studies were excluded based either on sample size or on differences in measurable parameters. [164][165][166][167][168][169][170][171] The studies assessed the success rate generally defined as more than 50% repigmentation of the body surface (or area/lesions) treated. Repigmentation was evaluated mainly visually, with or without photographs of treated areas recorded at the beginning and end of the treatment.…”

Section: Treatment Of Vitiligo a Review Of Clinical Trials Using Vitmentioning

confidence: 99%

New insights on therapy with vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo

Birlea¹,

Costin

Norris³

2009

Medicinal Research Reviews

View full text Add to dashboard Cite

Vitiligo is a progressive depigmenting disorder affecting 0.5-2% of the population worldwide in which destruction of functional melanocytes from epidermis is a composite of multiple processes influencing melanocyte function and survival. A number of studies have recently reported that the treatment with vitamin D compounds or their combination with ultraviolet light or corticosteroids enhances repigmentation in vitiligo; however, the causal relationship at the cellular and molecular levels has not so far been investigated. This review details the main intracellular pathways through which vitamin D ligands alone or in different combinations may contribute to pigment restoration in vitiligo, outlines the most recent achievements in vitiligo treatment using vitamin D analogs, and compares their efficacy with other treatment regimens in vitiligo. Based on the reviewed literature and data, we foresee the need for designing new vitamin D compounds to achieve maximal therapeutic efficacy. Such compounds should have high selectivity for melanocytes, stimulatory effects on melanogenesis, and minimal suppressive effects on melanocyte growth. An approach combining clinical investigations and focused research on the cellular and molecular mechanisms of vitiligo repigmentation will lead to finding better treatments for this disease.

show abstract

“…Pimecrolimus is effective in dermatoses such as atopic dermatitis, allergic contact dermatitis, lupus erythematosus, psoriasis, prurigo nodularis, papulopustular rosacea and vitiligo 7–11 …”

Section: Discussionmentioning

confidence: 99%

Treatment of disfiguring chronic graft versus host disease in a child with topical pimecrolimus

Zangrilli¹,

Campione²,

Diluvio³

et al. 2010

Pediatrics International

View full text Add to dashboard Cite

Key words chronic cutaneous graft-versus-host disease (GVHD), immune modulation therapy, pimecrolimus.Chronic cutaneous graft-versus-host disease (GVHD) is a severe clinical and pathological manifestation that occurs in patients after allogenic peripheral blood stem cell or bone marrow transplantation. 1 Acute and chronic forms of cutaneous GVHD show various manifestations including exanthema, erythrodermia and toxic epidermal necrolysis as acute reactions, and lichenoid or sclerodermatous changes as chronic reactions. 2 The beginning of the treatment of chronic GVHD is systemic immunosuppression and the efficacy of extracorporeal photopheresis, UVA1 phototherapy, and narrowband UVB phototherapy is currently under investigation for treatment of GVHD. 3 Nevertheless, cutaneous chronic GVHD may also respond to topical therapy such as corticosteroids, azathioprine, tacrolimus and pimecrolimus. 4,5 Pimecrolimus (SDZ ASM 981) is part of the new class of novel ascomycin immunomodulating macrolactams, and was developed for the treatment of inflammatory skin disease. 6 We report a case of a generalized cutaneous GVHD in a 9-year-old Iranian boy that occurred after bone-marrow transplantation for b-thalassemia major. The patient showed a significant improvement with topical pimecrolimus 1% cream twice daily for 9 weeks. Case reportA 9-year-old Iranian boy was admitted to our department in April 2005 from the Mediterranean Institute of Hematology due to disfiguring lesions on the face. His medical history included b-thalassemia major for which he underwent bone marrow transplantation six years earlier followed by chemotherapy and radiation. He successively developed multiple endocrinal disorders such as growth hormone deficiency, autoimmune thyroiditis, osteoporosis and hypothyroidism. Two years after bone marrow transplantation the patient presented with GVHD with minimal cutaneous and mucosal involvement. Afterwards he started having severe GVHD with recurrent attacks of chest infections from Pseudomonas Aeruginosa, mycoplasma, Streptococcus Pneumoniae and chronic bronchiolitis; also, cutaneous involvement was ingravescent. He was treated with systemic antibiotics, cyclosporine A and a low dose of cortisone, but he experienced many steroid-related toxicities, such as glaucoma and diabetes, obesity and mild hypertension.When the patient came to our institution he presented cutaneous chronic GVHD with erythematous, hyperpigmented and hypopigmented lesions. Poikilodermic lesions with scaling, reddish, pruritic plaque with severe atrophy were prevalent in the seborrheic areas of his face (Fig. 1). Diffuse multiple scleroatrophic lesions were visible on the trunk. Furthermore he presented mild dystrophy of the oral mucosa, palate and tongue and onicodystrophy. A punch biopsy of the affected skin was compatible with the sclerotic late stage of chronic GVHD. It showed atrophy of epidermidis, with orthokeratotic maturation, dilation of bloodstream small vessels of superficial derma and the presence of macrophages containing ...

show abstract

Two therapeutic challenges: facial vitiligo successfully treated with 1% pimecrolimus cream and 0.005% calcipotriol cream

Cited by 7 publications

References 9 publications

Efficacy of topical calcineurin inhibitors in vitiligo

Efficacy of topical calcineurin inhibitors in vitiligo

New insights on therapy with vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo

Treatment of disfiguring chronic graft versus host disease in a child with topical pimecrolimus

Contact Info

Product

Resources

About